Altium Capital Management LLC Sells 43,000 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Altium Capital Management LLC lowered its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 25.3% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 127,000 shares of the biotechnology company's stock after selling 43,000 shares during the quarter. Sarepta Therapeutics accounts for 4.4% of Altium Capital Management LLC's investment portfolio, making the stock its 4th largest holding. Altium Capital Management LLC owned 0.13% of Sarepta Therapeutics worth $15,442,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in SRPT. Manchester Capital Management LLC boosted its position in Sarepta Therapeutics by 86.6% during the fourth quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 156 shares during the last quarter. Newbridge Financial Services Group Inc. acquired a new position in Sarepta Therapeutics during the fourth quarter worth about $36,000. Steward Partners Investment Advisory LLC lifted its holdings in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 194 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in shares of Sarepta Therapeutics by 95.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 442 shares of the biotechnology company's stock valued at $54,000 after purchasing an additional 216 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company's stock.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.70% of the company's stock.

Sarepta Therapeutics Price Performance

SRPT traded up $2.58 during trading on Tuesday, reaching $57.81. The stock had a trading volume of 659,454 shares, compared to its average volume of 1,411,067. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The stock has a 50 day moving average of $81.12 and a two-hundred day moving average of $107.25. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25. The firm has a market capitalization of $5.61 billion, a price-to-earnings ratio of 46.29 and a beta of 0.93.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Needham & Company LLC cut their price target on Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a report on Thursday, April 3rd. Cantor Fitzgerald reissued an "overweight" rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, March 18th. HC Wainwright reaffirmed a "neutral" rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a research note on Wednesday, April 16th. Scotiabank decreased their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating on the stock in a report on Thursday, March 20th. Finally, Morgan Stanley reduced their target price on Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating on the stock in a research report on Friday, April 11th. Six analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $158.70.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.